SEC Form 4 · accession 0001144204-15-001702
Synthetic Biologics, Inc. · SYN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles Evan Ballantyne
Officer — Chief Financial Officer
Period of report
Jan 8, 2015
Accepted (ET)
Jan 12, 2015 · 6:11 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000894158
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF1 | $1.54 | Jan 8, 2015 | A | 200,000 | A | Jan 8, 2015 | Jan 8, 2025 | Common Stock | 200,000 | 200,000 | D |
Explanation of responses
- F1These options will vest quarterly on a pro rated basis over 36 consecutive months.